文献速递帕金森病与运动障碍认知障碍与痴呆

LRRK2帕金森病前驱期5-羟色胺和多巴胺转运体PET变化

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
PubMed 文献 · Lancet Neurol · 2017-03-20

两项横断面PET研究比较LRRK2突变携带者(伴或不伴帕金森病)、散发性帕金森病患者和健康对照。结果显示,伴帕金森病的LRRK2突变者多巴胺能变化与散发性帕金森病相似;不伴运动症状的LRRK2突变者纹状体、脑干和下丘脑5-羟色胺转运体结合升高,可能反映代偿性5-羟色胺能神经支配增加。

要点

  • LRRK2突变携带者无运动症状时,纹状体、脑干和下丘脑5-羟色胺转运体结合升高。
  • 伴帕金森病的LRRK2突变者多巴胺转运体和18F-FDOPA变化与散发性帕金森病相似。
  • 5-羟色胺能代偿变化可能先于运动症状出现,并影响非运动症状。

核心结论

  • 伴帕金森病的LRRK2突变者多巴胺能和5-羟色胺能变化与散发性帕金森病进展相似。
  • 无运动症状的LRRK2突变者纹状体、脑干和下丘脑5-羟色胺转运体结合升高,可能反映代偿性5-羟色胺能神经支配增加。

研究设计与样本

  • 在加拿大温哥华太平洋帕金森研究中心开展两项横断面PET研究。
  • 第一项研究纳入40例LRRK2突变携带者、63例散发性帕金森病患者和35例健康对照。
  • 第二项研究纳入16例LRRK2突变携带者、13例散发性帕金森病患者和9例健康对照。
  • 使用膜多巴胺转运体、18F-FDOPA、5-羟色胺转运体和VMAT2示踪剂进行PET显像。
  • 采用ANCOVA比较各组结合情况,校正年龄。

主要发现

  • 伴帕金森病的LRRK2突变者(n=15)纹状体多巴胺转运体结合和18F-FDOPA摄取降低,与病程相似的散发性帕金森病患者相当。
  • 无帕金森病的LRRK2突变者(n=25)18F-FDOPA摄取和多巴胺转运体结合高于散发性帕金森病患者,其中18F-FDOPA摄取与对照相当,多巴胺转运体结合低于对照。
  • 校正年龄后,皮层5-羟色胺转运体结合各组间无显著差异;所有伴帕金森病者纹状体VMAT2结合降低,1例无帕金森病的LRRK2突变者呈不对称降低。

关键数值与推荐

  • 帕金森病诊断由运动障碍专科神经科医生根据英国帕金森病学会脑库标准做出。
  • LRRK2携带状态通过双向Sanger测序确认。
  • 第一项研究纳入1999年7月至2012年1月转诊的LRRK2突变携带者。

临床怎么用

  • 对于LRRK2突变携带者,PET可检测前驱期多巴胺能和5-羟色胺能变化。
  • 无运动症状的LRRK2突变者5-羟色胺转运体结合升高可能提示代偿性5-羟色胺能神经支配增加。
  • 这些变化可能解释LRRK2帕金森病的非运动症状和左旋多巴长期反应差异。

局限性

  • 两项研究均为横断面设计,无法确定变化的时间顺序。
  • 第二项研究样本量较小(LRRK2突变携带者16例、散发性帕金森病患者13例、健康对照9例)。
  • 研究未报告纵向随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with Parkinson's disease can show premotor neurochemical changes in the dopaminergic and non-dopaminergic systems. Using PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutation carriers with Parkinson's disease and individuals with sporadic Parkinson's disease, and whether LRRK2 mutation carriers without motor symptoms show PET changes. METHODS: We did two cross-sectional PET studies at the Pacific Parkinson's Research Centre in Vancouver, BC, Canada. We included LRRK2 mutation carriers with or without manifest Parkinson's disease, people with sporadic Parkinson's disease, and age-matched healthy controls, all aged 18 years or older. People with Parkinson's disease were diagnosed by a neurologist with movement disorder training, in accordance with the UK Parkinson's Disease Society Brain Bank criteria. LRRK2 carrier status was confirmed by bidirectional Sanger sequencing. In the first study, LRRK2 mutation carriers with or without manifest Parkinson's disease who were referred for investigation between July, 1999, and January, 2012, were scanned with PET tracers for the membrane dopamine transporter, and dopamine synthesis and storage (18F-6-fluoro-L-dopa; 18F-FDOPA). We compared findings with those in people with sporadic Parkinson's disease and age-matched healthy controls. In the second study, distinct groups of LRRK2 mutation carriers, individuals with sporadic Parkinson's disease, and age-matched healthy controls seen from November, 2012, to May, 2016, were studied with tracers for the serotonin transporter and vesicular monoamine transporter 2 (VMAT2). Striatal dopamine transporter binding, VMAT2 binding, 18F-FDOPA uptake, and serotonin transporter binding in multiple brain regions were compared by ANCOVA, adjusted for age. FINDINGS: Between January, 1997, and January, 2012, we obtained data for our first study from 40 LRRK2 mutation carriers, 63 individuals with sporadic Parkinson's disease, and 35 healthy controls. We identified significant group differences in striatal dopamine transporter binding (all age ranges in caudate and putamen, p<0·0001) and 18F-FDOPA uptake (in caudate: age ≤50 years, p=0·0002; all other age ranges, p<0·0001; in putamen: all age ranges, p<0·0001). LRRK2 mutation carriers with manifest Parkinson's disease (n=15) had reduced striatal dopamine transporter binding and 18F-FDOPA uptake, comparable with amounts seen in individuals with sporadic Parkinson's disease of similar duration. LRRK2 mutation carriers without manifest Parkinson's disease (n=25) had greater 18F-FDOPA uptake and dopamine transporter binding than did individuals with sporadic Parkinson's disease, with 18F-FDOPA uptake comparable with controls and dopamine transporter binding lower than in controls. Between November, 2012, and May, 2016, we obtained data for our second study from 16 LRRK2 mutation carriers, 13 individuals with sporadic Parkinson's disease, and nine healthy controls. Nine LRRK2 mutation carriers without manifest Parkinson's disease had significantly elevated serotonin transporter binding in the hypothalamus (compared with controls, individuals with LRRK2 Parkinson's disease, and people with sporadic Parkinson's disease, p<0·0001), striatum (compared with people with sporadic Parkinson's disease, p=0·02), and brainstem (compared with LRRK2 mutation carriers with manifest Parkinson's disease, p=0·01), after adjustment for age. Serotonin transporter binding in the cortex did not differ significantly between groups after age adjustment. Striatal VMAT2 binding was reduced in all individuals with manifest Parkinson's disease and reduced asymmetrically in one LRRK2 mutation carrier without manifest disease. INTERPRETATION: Dopaminergic and serotonergic changes progress in a similar fashion in LRRK2 mutation carriers with manifest Parkinson's disease and individuals with sporadic Parkinson's disease, but LRRK2 mutation carriers without manifest Parkinson's disease show increased serotonin transporter binding in the striatum, brainstem, and hypothalamus, possibly reflecting compensatory changes in serotonergic innervation preceding the motor onset of Parkinson's disease. Increased serotonergic innervation might contribute to clinical differences in LRRK2 Parkinson's disease, including the emergence of non-motor symptoms and, potentially, differences in the long-term response to levodopa. FUNDING: Canada Research Chairs, Michael J Fox Foundation, National Institutes of Health, Pacific Alzheimer Research Foundation, Pacific Parkinson's Research Institute, National Research Council of Canada.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Wile DJ, Agarwal PA, Schulzer M, et al. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Lancet Neurol. 2017. PMID: 28336296. doi:10.1016/S1474-4422(17)30056-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。